ASCO 2023 | SELISARC: selinexor with gemcitabine in sarcoma

Javier Martin Broto, MD, PhD, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain, provides an overview of the Phase I SELISARC trial (NCT04595994) of selinexor plus gemcitabine in patients with selected sarcoma subtypes. Combination of selinexor with chemotherapy demonstrated promising efficacy, and the investigational therapy had manageable toxicity. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.